Tocilizumab in Chronic Inflammatory CPPD Disease
Condition(s) studied
Investigational drug(s) / intervention(s)
Tocilizumab: Tocilizumab, 8 mg/kg/month, IV infusion for 3 months Tocilizumab, an anti-IL-6R monoclonal antibody, was approved in January 2009 for the treatment of rheumatoid arthritis. Its indications have since been extended, particularly for the treatment of giant cell arteritis, juvenile chronic arthritis, and severe cytokine release syndrome induced by chimeric antigen receptor T-cell (CAR-T) therapy.
Placebo: Saline placebo, IV infusion / month for 3 months
Study summary
The aim of this clinical trial is to determine the efficacy of tocilizumab (an IL-6 inhibitor) in treatment-refractory chronic inflammatory forms of CPPD.
The main questions this trial aims to answer are:
* Can tocilizumab improve joint pain in patients with chronic inflammatory CPPD disease?
* Does tocilizumab improve quality of life in patients with chronic inflammatory CPPD disease?
Participants will receive a monthly infusion of tocilizumab or placebo for three months.
Eligibility
Primary outcome measure(s)
- Change in overall pain VAS — 6 months
Overall pain will be assessed, after 24 hours of discontinuation of analgesics, using a visual analogue scale (VAS) ranging from 0 (no pain) to 100 mm (worst pain ever experienced), at inclusion, before each infusion at months M1, M2, M3, then at M4 (primary outcome) and M6.
Trial sites (12)
| Facility | City | Region | Status |
|---|---|---|---|
| Groupe Hospitalier de l'Institut Catholique de Lille | Lomme | Lille | |
| Lariboisière hospital | Paris | Paris Paris | |
| Centre Hospitalier Sud-Francilien | Corbeil-Essonnes | Paris | |
| CHU de Dijon | Dijon | France | |
| CHU de Nantes | Nantes | France | |
| Hôpital Bichat Claude-Bernard | Paris | France | |
| Hôpital de la Croix Saint-Simon | Paris | France | |
| Hôpital Tenon | Paris | France | |
| Groupe Hospitalier Intercommunal Le Raincy-Montfermeil | Paris | France | |
| Hôpital Le Kremlin Bicêtre | Paris | France | |
| CHU de Rennes | Rennes | France | |
| CHU de Saint-Étienne | Saint-Etienne | France |
On this site
📄 Actemra (tocilizumab) drug profile →More Assistance Publique - Hôpitaux de Paris trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07254637 on ClinicalTrials.gov ↗ ← All trials in France